Pharmaceutical

China’s NMPA approves Antengene’s XPOVIO for DLBCL

China's NMPA approved Antengene’s new indication of XPOVIO for adults with relapsed or refractory diffuse large B-cell lymphoma.

Jul 10, 2024 - 04:00
China’s NMPA approves Antengene’s XPOVIO for DLBCL
China's NMPA approved Antengene’s new indication of XPOVIO for adults with relapsed or refractory diffuse large B-cell lymphoma.
Read the original article

Tags:

Previous Article

UK pharma group reprimands Novo Nordisk for undisclosed payments

Next Article

Mesoblast Resubmits BLA For Ryoncil Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: Peter Hotez is not alone: Online harassment of doctors is a public health issue

Opinion: Peter Hotez is not alone: Online harassment of...

Jun 24, 2023

Study shows autistic people are more likely to engage in self-harm — but not because of autism

Study shows autistic people are more likely to engage i...

Aug 9, 2023

Leading innovators in anti-viral antigen-based compositions for the pharmaceutical industry

Leading innovators in anti-viral antigen-based composit...

May 8, 2023